ºÚÁÏÍø

Juan Song's lab publishes a paper in Neuron showing the cell-signaling role of a neuropeptide called cholecystokinin, which is important in regulating neural stem cells and creating adult-born neurons within the hippocampus of the brain.

This work, published in Cell and led by the Roth lab sets the stage for the discovery of new kinds of antidepressants, anti-anxiety drugs, and treatments for substance use disorders. Kuglee Kim is co-first author on the paper.

Congratulations to Pharmacology graduate student Raquel C. Martinez Chacin, who is first author on a paper published in Nature Structural and Molecular Biology Journal! The paper by the Brown Lab in collaboration with the Emanuele Lab, Jean Cook lab, and other researchers at ºÚÁÏÍø and the Research Institute of Molecular...

ºÚÁÏÍø researchers led by Klaus Hahn, PhD, John Sondek, PhD, and Daniel Marston, PhD, and colleagues at the University of Texas Southwestern reveal the inner workings of cellular communication and processes important for cell migration and potentially metastasis.

Researchers led by Blossom Damania, PhD, reported that Kaposi sarcoma-associated herpesvirus, a virus linked to three human cancers, uses a protein produced by its human host to come out of hiding and reactivate.

The lab of Bryan Roth, MD, PhD, was part of a large research project led by the University of California-San Francisco to identify viral proteins and virus-host protein interactions that could become important drug targets to treat people with COVID-19.

Roth Lab team and collaborators create molecules that selectively target the MT1 melatonin receptor to modulate the biological clocks in animal models of jet lag.

The technique, dubbed VEGAS and created in the lab of Bryan L. Roth, works in mammalian cells and can yield useful new molecules within days, providing scientists with a powerful new research tool and a potential route to better therapeutics for various diseases.

Researchers in the ºÚÁÏÍø Lineberger Comprehensive Cancer Center led by Lee Graves, PhD, have uncovered the mechanism that explains how an investigational cancer therapeutic might be working.

In lab experiments, researchers led by Michael Emanuele, PhD, found that the enzyme USP21 protects the protein FOXM1, which has been implicated in basal-like breast cancer progression, metastasis, and poor patient outcomes.